Neumora officer sells 1,436 shares under 10b5-1 plan

Neumora Therapeutics officer Michael Lee Milligan reported an open-market sale of 1,436 shares of common stock at $3.565 per share.

Rhea-AI Filing Summary

Neumora Therapeutics officer Michael Lee Milligan reported an open-market sale of 1,436 shares of common stock at $3.565 per share. The February 17 transaction was executed under a pre-established Rule 10b5-1 trading plan that automatically sells shares on each covered restricted stock unit vesting date to satisfy withholding obligations.

After this sale, Milligan directly held 21,034 Neumora common shares. The filing describes an automated, plan-driven disposition rather than a discretionary trade decision.

Insider Trade Summary

Net Seller: 1,436 shares

Net Sell 1 txn

Insider Milligan Michael Lee

Role See Remarks

Sold 1,436 shs ($5K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,436	$3.565	$5K

Holdings After Transaction: Common Stock — 21,034 shares (Direct)

Footnotes (1)

1. F1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Neumora Therapeutics (NMRA) report for Michael Lee Milligan?

Neumora reported that officer Michael Lee Milligan sold 1,436 shares of common stock. The shares were sold at $3.565 each under a Rule 10b5-1 trading plan tied to restricted stock unit vesting and related tax withholding requirements.

At what price were the Neumora (NMRA) shares sold in Michael Milligan’s Form 4 filing?

The reported Neumora shares were sold at $3.565 per share. This price applies to the 1,436 common shares disposed of in the open-market transaction executed pursuant to Milligan’s Rule 10b5-1 trading plan for withholding-tax coverage.

How many Neumora (NMRA) shares does Michael Lee Milligan hold after this Form 4 sale?

Following the reported sale, Michael Lee Milligan directly owns 21,034 Neumora common shares. This post-transaction holding reflects the reduction from selling 1,436 shares in an automatic 10b5-1 plan trade associated with restricted stock unit vesting.

Was the Neumora (NMRA) insider sale by Michael Milligan discretionary or under a 10b5-1 plan?

The sale was executed under a Rule 10b5-1 trading plan, not as a discretionary trade. The plan, adopted August 30, 2024, automatically sells shares on each relevant restricted stock unit vesting date to cover applicable tax withholding obligations.

What is the purpose of Michael Milligan’s Rule 10b5-1 plan mentioned in Neumora’s Form 4?

The Rule 10b5-1 plan automatically sells Neumora shares that would otherwise be issued upon restricted stock unit vesting. The goal is to generate enough proceeds to satisfy required tax withholding, reducing the need for separate cash payments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 05:04 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milligan Michael Lee

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL WAY, SUITE 1

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		1,436	D	$3.565	21,034	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.

Remarks:

Title: Chief Financial Officer & Principal Accounting Officer

	/s/ Michael Lee Milligan	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.